Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
CytoVac AB logo — Biotech company with Phase II Clinical Trials - ALECSAT - CA...

CytoVac AB

Biotech company with Phase II Clinical Trials - ALECSAT - CAR-T cell therapy - Orphan Drug

Founded 2008 10 employees Venture round Biotechnology, Health Care

General Information

Company Name CytoVac AB
Founded Year 2008
Employees 10
Industries Biotechnology, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with CytoVac AB. To contact CytoVac AB, visit cytovac.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About CytoVac AB

Cytovac has the key to immunotherapy Cytovac is a growing Danish biotech company, focusing on development of a cancer treatment that uses the body’s own immune system. Promising results gained by the dedicated research team over a number of years, have brought about the development of the ALECSAT therapy. ALECSAT is a therapy based on injection of activated cells from the immune system. These cells will attack the cancer cells and activate the immune system in the patients. As Cytovac solely apply the patient’s own cells, this therapy is gentle and without the serious side effects normally associated with cancer treatment. Cytovac has been granted Orphan Drug Designation by the European (EMA) as well as the American (FDA) medicines agencies in support to the company’s brain-cancer project. Cytovac has generated convincing data with the ALECSAT treatments in three clinical phase I trials targeted at treatment of prostate cancer, pancreatic cancer and brain cancer. So far more than 100 cancer patients have been treated, with more than 250 doses of ALECSAT. So Cytovac has a platform that may prove to be an efficacious treatment for several types of cancer. Cytovac has since 2015 concentrated all clinical efforts on brain cancer, and here the company is currently conducting clinical phase II trials. Cytovac is dedicated to treatment of cancer by using our key to immunotherapy.

No funding data available for CytoVac AB yet.

CytoVac AB Alternatives & Competitors

CytoVac AB vs
Lytix Biopharma
Lytix Biopharma Norway

A clinical-stage immuno-oncology company developing proprietary oncolytic drugs as a novel therapy t...

Grant
15 employees
Biotechnology, Health Care
CytoVac AB vs
Northwest Biotherapeutics
Northwest Biotherapeutics United States

Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering,...

Post-IPO Debt
16 employees
Biotechnology, Health Care
CytoVac AB vs
Vital Therapies
Vital Therapies

Pioneering the future of liver therapy with innovative cell-based treatments for acute liver failure...

Private Equity
Biotechnology, Health Care

FAQ About CytoVac AB

Biotech company with Phase II Clinical Trials - ALECSAT - CAR-T cell therapy - Orphan Drug
CytoVac AB was founded in 2008.
CytoVac AB operates in Biotechnology and Health Care.
CytoVac AB has approximately 10 employees.
Top alternatives and competitors to CytoVac AB include Lytix Biopharma, Northwest Biotherapeutics, Vital Therapies, AbilityPharma, MedGene Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CytoVac AB and Lytix Biopharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CytoVac AB, https://bouncewatch.com/company/cytovac-ab, updated 10 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes